Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Surgical Endoscopy
Published in: Surgical Endoscopy 8/2011

01-08-2011 | Letter

Challenges with identification of angiogenesis biomarkers in cancer

Authors: Eugenia Halkia, Nikolaos Kalinoglou

Published in: Surgical Endoscopy | Issue 8/2011

Login to get access

Excerpt

Angiogenesis, the development of new blood vessels, plays an important role in cancer formation and metastasis. Therefore, antiangiogenic therapy for cancer treatment was developed and has become very popular in recent years. Inhibiting new tumor vessel formation and blood supply by agents can have therapeutic effects on cancer. This old concept recently has been translated into the development of targeted agents, such as bevacizumab (Avastin), that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. …
Literature
1.
2.
Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9:1413–1416PubMedCrossRef
3.
Shantha Kumara HM, Grieco MJ, Yan X, Kalady MF, Di Maggio V, Kim DG, Hyman N, Feingold DL, Whelan RL (2010) Minimally invasive colorectal resection for cancer is associated with a short-lived decrease in soluble Tie-2 receptor levels, which may transiently inhibit VEGF-mediated angiogenesis (via altered blood levels of free Ang-1 and Ang-2). Surg Endosc 24:2581–2587PubMedCrossRef
4.
Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651PubMedCrossRef
5.
Liakakos T, Roukos DH (2008) Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc 22:1402–1404PubMedCrossRef
6.
Katsios GC, Baltogiannis G, Roukos DH (2010) Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther 10:473–476PubMedCrossRef
7.
Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22:1553–1555PubMedCrossRef
8.
Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250:349–350PubMedCrossRef
9.
Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249:695–696PubMedCrossRef
10.
Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22:1405–1406PubMedCrossRef
11.
Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11:1039–1043PubMedCrossRef
12.
Roukos DH (2010) Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 4:583–586PubMedCrossRef
13.
Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10:541–545PubMedCrossRef
14.
Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10:33–48PubMedCrossRef
15.
Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Per Med 7:347–350CrossRef
16.
Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250PubMedCrossRef
17.
Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16:2678–2681PubMedCrossRef
18.
Roukos DH (2011) Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices 8(2):123–126PubMedCrossRef
19.
Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128PubMedCrossRef
20.
Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995; author reply 1995–1996
21.
Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-Wide association studies be the solution for cancer complexity like Alexander the great for the “gordian knot”? Ann Surg Oncol 16(3):774–775PubMedCrossRef
22.
Roukos DH, Kappas AM, Tsianos E (2002) Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 9(7):607–609PubMedCrossRef
23.
Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10:718–721PubMedCrossRef
24.
Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9(10):941–943PubMed
25.
Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068PubMedCrossRef
26.
Roukos DH (2011) “Big” science: genome regulatory networks and novel molecular tools to improve health. Expert Rev Mol Diagn 11(2):123-126. doi: 10.​1586/​ERM/​11.​4
27.
Roukos DH (2011) Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol 18(1):12–15PubMedCrossRef
28.
Roukos DH (2011) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J 11(2):81–92PubMedCrossRef
29.
Roukos DH (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices 7(6):723–726PubMedCrossRef
Metadata
Title
Challenges with identification of angiogenesis biomarkers in cancer
Authors
Eugenia Halkia
Nikolaos Kalinoglou
Publication date
01-08-2011
Publisher
Springer-Verlag
Published in
Surgical Endoscopy / Issue 8/2011
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-011-1623-3

Other articles of this Issue 8/2011

Surgical Endoscopy 8/2011 Go to the issue

OriginalPaper

Supplementation of Los Angeles classification with esophageal mucosa index of hemoglobin can predict the treatment response of erosive reflux esophagitis

OriginalPaper

A randomized prospective study of single-port and four-port approaches for hysterectomy in terms of postoperative pain

Endoluminal Surgery

Reliability of gastric access closure with the self-approximating transluminal access technique (STAT) for NOTES

Letter

Modification of laparoscopic subtotal cholecystectomy

OriginalPaper

The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis

OriginalPaper

Laparoscopic approach to distal and subtotal pancreatectomy: a clockwise technique